LAB vs VTR · rev $174.4M vs P/E 149, rev $4.92B
Standard Biotools Inc (LAB) versus Ventas Inc (VTR) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Ventas Inc (VTR) is a reit - healthcare facilities company listed on NYSE.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported VTR revenue for 2024-12-31 was $4.92B. Net income was $88.4M. Revenue was up 9.5% from 2023-12-31 to 2024-12-31. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
LAB currently screens at market cap $317.1M. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
Not investment advice. Open the LAB and VTR stock pages for the full models.
Not investment advice.